Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.

Abstract

Mineralocorticoid receptor antagonists have been used in patients with aldosterone-producing adenomas (APAs) as a test designed to predict the blood pressure (BP) outcome of surgery. They are commonly used in patients undergoing adrenalectomy to reduce BP and increase plasma potassium levels during the preoperative period. A small number of studies have compared the effects of surgery and mineralocorticoid antagonists either on BP, on serum potassium levels, or on the incidence of cardiovascular and renal outcomes in patients with primary aldosteronism with or without an APA; these studies found no difference between the two therapeutic options. Mineralocorticoid receptor antagonists can be used as a maintenance treatment for patients with APAs, who are judged to be poor operative risks or who do not want to undergo surgery.

• Authors: Laurence Amar, Aurélien Lorthioir, Michel Azizi, Pierre-Francois Plouin
• Journal: European journal of endocrinology (Eur J Endocrinol) Vol. 172 Issue 3 Pg. R125-9 (Mar 2015) ISSN: 1479-683X [Electronic] England
• PMID: 25315875 (Publication Type: Journal Article, Review)
• Copyright: © 2015 European Society of Endocrinology.

Chemical References

• Mineralocorticoid Receptor Antagonists
• Aldosterone

Topics

• Adrenocortical Adenoma (drug therapy, metabolism)
• Aldosterone (metabolism)
• Humans
• Hyperaldosteronism (drug therapy, metabolism)
• Mineralocorticoid Receptor Antagonists (therapeutic use)